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Abstract
Estrogen receptors (ERα and ERβ) are estrogen-regulated transcription factors that play important roles in the development and progression of
breast cancer. The biological function of ERs has been shown to be modulated by ER-interacting proteins. However, the ER-interacting proteins
that not only activate MAPK and AKT, two important growth regulatory protein kinases, but also increase growth related estrogen-responsive
gene expression remain unknown. Here, we report that hematopoietic PBX-interacting protein (HPIP) interacts both with ERα and with ERβ, and
increases ERα target gene expression through activation of MAPK and AKT and enhanced ERα phosphorylation. ERβ inhibits ERα target gene
expression, possibly by competition of ERβ with ERα for binding to HPIP, and by a decrease in available ERα for HPIP binding through the
interaction of ERβ with ERα. Furthermore, HPIP increases breast cancer cell growth. These data suggest that HPIP may be an important regulator
in ER signaling and that the relative ratio of ERβ to ERα may be important for HPIP function.
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Estrogen receptor (ER) plays an important role in the
development and progression of breast cancer [1–3]. ER has
two subtypes, ERα and ERβ [4–6]. They belong to steroid/
thyroid hormone superfamily of transcription factors. ERs
contain N-terminal estrogen-independent and C-terminal estro-
gen-dependent activation function domains (AF1 and AF2,
respectively). The DNA-binding domain (DBD) of the ERs is
centrally located. The ligand-binding domain, overlapping AF2,
shows 58% homology between ERα and ERβ. The DBD is
identical between the two receptors except for three amino acids.
However, the N-terminus containing the AF1 domain of ERβ
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binding site because of the high degree of sequence homology
they share in their ligand- and DNA-binding domains [7].
The classic effects of estrogens are mediated through binding
to ERs, which regulate gene expression by recruiting cofactors
and binding to an estrogen-responsive element (ERE) in the
nucleus [8,9]. Other actions of estrogens involve interaction of
ERs with other transcription factors, such as activating protein 1
(AP-1) and GC-box binding protein (SP-1), which in turn bind to
DNA and regulate transcription [10,11]. These events are
generally termed estrogen genomic effects because of the
involvement of gene transcription. Some estrogen-responsive
genes, such as pS2 and cathepsin D, two ERα target genes, have
been identified and well characterized by examination of the
estrogen genomic effects [12,13]. However, little is known about
ERβ target genes. Recently, estrogen has been shown to induce
rapid non-genomic pathways through interaction with membrane
receptors, especially ERs [14–17]. The rapid non-genomic actions
of estrogens include activation of mitogen-activated protein
kinase (MAPK), protein kinase B/AKT, and intracellular second
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of phosphatidylinositol-3-OH kinase (PI3K), resulting in the
activation of AKT [21]. AKT phosphorylates ERα at serine 167,
thereby increasing transcriptional activation by ER, as determined
by estrogen-responsive reporter assay [22]. The MAPK pathway
can also interact with ER. MAPK/ERK1/2 can phosphorylate
ERα at serine 118 to turn on receptor transactivation [23–25].
Although many ER-interacting proteins have been shown to
regulate estrogen-responsive gene expression, the ER-interact-
ing proteins that not only activate both MAPK and AKT, two
important growth regulatory protein kinases, but also stimulate
expression of estrogen-responsive proteins remain unknown. In
this study, we have identified and characterized an ERα- and
ERβ-interacting protein, hematopoietic pre-B cell leukemia
transcription factor (PBX)-interacting protein (HPIP). HPIP was
shown to be a corepressor for the transcription factor PBX
[26,27]. The function of HPIP, however, is largely unknown.
Here, we show that HPIP increases ERα target gene expression
through activation of MAPK and AKT and enhanced ERα
phosphorylation. ERβ can compete with ERα for binding to
HPIP and inhibit the expression of the ERα target gene pS2.
2. Materials and methods
2.1. Plasmids
The reporter construct pS2-Luc and expression vector for ERα and ERβ have
been described previously [28–30]. The ERα (S167A) mutant construct was made
by recombinant PCR.TheFLAG-taggedHPIP expression plasmidwas cloned into a
pcDNA3 vector linked with FLAG at the amino terminus by PCR using mammary
cDNA library (Clontech) as the template. Plasmids encoding GST-fusion proteins
were prepared by amplification of each sequence by standard PCRmethods, and the
resulting fragments were cloned in frame into pGEX-KG (Amersham Pharmacia
Biotech) using appropriate sites. All of the constructswere confirmed by sequencing.
2.2. Stable transfection
Stable transfection of expression vector for FLAG-HPIP or HPIP siRNA into
MCF7 cellswere performedusingLipofectamine 2000 (Invitrogen). Transfected cells
were selected in 500 μg/ml G418 (Invitrogen) for approximately 2 months. Pooled
clones or individual clones were screened by Western blot using anti-FLAG or anti-
HPIP antibody. Similar resultswere observedwith individual clones or pooled clones.
2.3. Yeast two-hybrid assay
The bait plasmid pGBKT7-ERβ-AF2 (255–504) was used to screen a
human mammary gland cDNA library fused to the GAL4 activation domain in
pACT2 (Clontech) according to the manufacturer's instructions. Transformants
were plated on synthetic medium lacking tryptophan, leucine, adenine and
histidine but containing 1 mM 3-aminotriazole. Approximately one million
transformants were screened. The candidate clones were rescued from the yeast
cells and reintroduced back to the same yeast strain to verify the interaction
between the candidates and the ERβ AF2 bait. The specificity of the interaction
was determined by comparing the interactions between the candidates and
various bait constructs. The unrelated prey plasmid pACT2-lamin and the empty
vector pACT2 were used as negative controls.
2.4. Antibody production
The GST-HPIP (1–137) fusion protein was expressed in bacteria and
purified using glutathione-Sepharose 4B beads according to the manufacture's
protocol (Amersham Pharmacia). To generate polyclonal HPIP antibody, the
purified GST-HPIP (1–137) protein was injected subcutaneously into each oftwo BALB/c female mice. Sera from the immunized mice were collected and
purified by affinity chromatography according to the manufacture's instructions
(Pierce).
2.5. Luciferase assay
MCF7 cells were maintained in DMEM medium (Invitrogen) supplemented
with 10% fetal bovine serum (FBS). For transfection, cells were seeded in 24-well
plates containing phenol red-free DMEMmedium (Invitrogen) supplemented with
5% charcoal-stripped FBS (Hyclone). The cells were transfected using Lipofecta-
mine 2000 (Invitrogen) with 0.2 μg of pS2-Luc, 1.0 μg of the expression vector for
HPIP or HPIP siRNA, and 0.1 μg ofβ-galactosidase reporter as an internal control.
After treatment with 10 nM 17β-estradiol (E2), 100 nM ICI182,780, 40 μM
PD98059, or 50μMLY294002 for 24 h, the cells were harvested. Cell extracts were
analyzed for luciferase and β-galactosidase activities as described previously [28].
2.6. GST pull-down assay
The GST alone and GST-fusion proteins were expressed in bacteria and
bound to glutathione-Sepharose beads according to the manufacturer's
instructions (Amersham Pharmacia). The expression plasmid for the ERα or
ERβ was used for in vitro transcription and translation in the TNT system
(Promega). The 35S-labeled ERα or ERβ was incubated with approximately
1 μg of GST-fusion protein bound to glutathione-Sepharose beads in 500 μl
binding buffer (50 mM Tris–HCl, pH7.5, 150 mM NaCl, 1 mM EDTA, 0.3 mM
DTT, 0.1% NP-40 and protease inhibitor tablets from Roche) at 4 °C. The beads
were precipitated, washed four times with binding buffer, eluted by boiling in
SDS sample buffer and analyzed by SDS-PAGE. After electrophoresis,
radiolabeled proteins were visualized by autoradiography.
2.7. Coimmunoprecipitation
For transfection-based coimmunoprecipitation assays, 293T cells were
transfected with the indicated plasmids using Lipofectamine 2000 (Invitrogen),
lysed in 500 μl lysis buffer (50 mM Tris at pH8.0, 500 mM NaCl, 0.5% NP-40,
1 mM DTT and protease inhibitor tablets from Roche), and immunoprecipitated
with anti-FLAG agarose beads (Sigma-Aldrich) overnight at 4 °C. The beads
were washed four times with the lysis buffer, and eluted in SDS sample buffer.
The eluted proteins were separated by SDS-PAGE, followed byWestern blotting
with the indicated antibodies according to the standard procedures.
For detecting interaction of endogenous ERα or ERβ with HPIP, human
breast cancer MCF7 cells were lysed in 500 μl lysis buffer and immunopre-
cipitated with anti-ERα, anti-ERβ or control serum (Santa Cruz). After
extensive washing with the lysis buffer, the immunoprecipitates were resolved
by SDS-PAGE, followed by Western blot analysis using anti-HPIP.
2.8. siRNA generation
siRNAwas designed using the web-based insert design tool at www.ambion.
com/techlib/misc/psilencer_converter.html. The pSilencer2.1-U6 neo vector
(Ambion)-based siRNA was made according to the manufacture's instructions.
The cDNA target sequences of siRNAs for HPIP were AGCAGCTTGGAT-
CAGGGAG corresponding to the coding region 405–423 relative to the first
nucleotide of the start codon. Plasmid pSilencer2.1-U6 neo Negative Control
(Ambion) was used as a control vector. Transient transfection of the vector-
based siRNA into MCF7 cells was performed using Lipofectamine 2000
according to the manufacture's instructions (Invitrogen).
2.9. Cell growth assay
Cells were seeded in 24-well plate with 10% FBS–DMEM. The medium
was changed at day 3. Cell growth was analyzed by crystal violet assay as
described previously [29]. Briefly, cells were fixed by 1% glutaraldehyde for
15 min and stained with 0.5% crystal violet for 15 min at room temperature.
Plates were washed with distilled water several times and air-dried. The dye was
eluted by Sorenson's solution for 30 min at room temperature with constant
shaking. A mircroplate reader was used to read aliquots of eluant at 590 nm.
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Statistical significance was determined by Student's t-test. A p value b0.05
was considered statistically significant.3. Results
3.1. Identification of HPIP as an ERβ-interacting protein
To identify proteins that interact with ERβ, we screened a
human mammary cDNA library using amino acids 255–504 of
ERβ containing part of hinge region and entire AF2 domain as
bait in the yeast two-hybrid system. HPIP was identified as an
ERβ-interacting protein. The specificity of this interaction wasFig. 1. Identification of HPIP and preparation of HPIP-specific antibody.
(A) Identification of HPIP as an ERβ-interacting protein by the yeast two-hybrid
system. AH109 yeast cells were transformed with different plasmids (bait and
prey) and grown on SD/-Trp-Leu-His-Ade. +, grown within 96 h; −, no growth
within 96 h. Positive colonies were tested for β-galactosidase activity. +, turned
blue within 2 h; −, did not turn blue within 2 h. (B) Mapping of the HPIP
interaction region in ERβ. AH109 cells were transformed with different
constructs and analyzed as in (A). (C) Characterization of anti-HPIP mouse
antibody by immunoblotting. The lysates from 293T cells transfected with
FLAG-HPIP or its empty vector were prepared and the proteins detected with
anti-FLAG (left panel) or anti-HPIP (right panel) antibody. (D) Expression of
HPIP in different human cell lines. HPIP expression was detected by Western
blot with anti-HPIP using proteins from indicated human cell lines.confirmed in a direct two-hybrid binding assay (Fig. 1A).
Transformation of yeast cells with HPIP in pACT2 vector
together with the GAL4 DNA-binding domain (DBD) in
pGBKT7 vector or together with an unrelated protein, lamin C,
fused to the GAL4 DBD instead of ERβ(255–504), did not
activate the ade, his and lacZ reporter genes, suggesting the
specific interaction of HPIP with ERβ.
To determine whether HPIP specifically interacts with amino
acids 255–504 of ERβ, different ERβ mutants were created for
yeast two-hybrid experiments. HPIP did not interact with
ERβ(1–145) containing the AF1, ERβ(131–324) containing
the DBD and hinge region, and ERβ(490–530) (Fig. 1B).
3.2. Generation of HPIP-specific antibody and detection of
HPIP protein
Since HPIP antibody is not commercially available, HPIP
polyclonal antibody was developed. To examine if the HPIP
antibody we produced can recognize HPIP protein, 293T cells
were transfected with expression vector for FLAG-tagged HPIP
or its empty vector control. Immunoblotting of whole cell
extracts with anti-FLAG or anti-HPIP demonstrated a specific
single band of a molecular weight of ~90 kDa (Fig. 1C).
Immunoblotting with anti-HPIP showed a single band in 293T
cells transfected with the control vector, suggesting that 293T
cells expressed endogenous HPIP (Fig. 1C, right panel). Due to
the small size of the FLAG tag (18 amino acids), we could not
clearly distinguish FLAG-HPIP from endogenous HPIP. Using
the specific anti-HPIP antibody, HPIP protein with varying
levels was detected in all of the breast cancer cell lines tested
(Fig. 1D).
3.3. HPIP interacts both with ERα and with ERβ in mammalian
cells
Since the amino acid sequence of ERβ(255–504) we used in
the yeast two-hybrid shares a high degree of similarity with the
corresponding region of ERα, the possibility that HPIP could
interact with ERα and ERβ was investigated by coimmuno-
precipitation. 293T cells were transfected with FLAG-HPIP
and ERα or ERβ, and cultured in the absence or presence of
10 nM 17β-estradiol (E2). FLAG-HPIP was immunoprecipi-
tated (IP) from cell lysates by anti-FLAG and analyzed for ERα
or ERβ binding by immunoblotting (IB). FLAG-HPIP could
be coimmunoprecipitated in the presence of ERα or ERβ
(Fig. 2A and B).
E2 increased the interaction of FLAG-HPIP with ERα or
ERβ. Endogenous HPIP was also found to be specifically
coimmunoprecipitated with endogenous ERα or ERβ (Fig. 2C
and D). These data strongly suggest that HPIP interacts with
ERα or ERβ in vivo.
3.4. Mapping of interaction regions of ERα and ERβ in HPIP
To define which regions of HPIP binds to ERα or ERβ, GST
pull-down experiments were performed. ERα and ERβ bound
three HPIP fragments (HPIP(138–220), HPIP(328–561) and
Fig. 2. HPIP interacts with ERα and ERβ in mammalian cells. (A and B)
Interaction of overexpressed HPIP with overexpressed ERα or ERβ in
mammalian cells. 293T cells were transfected with expression plasmids as
indicated in the presence or absence of 10 nm E2. Immunoprecipitation (IP) was
performed using anti-FLAGmonoclonal antibody, and immunoblotted (IB) with
anti-ERβ (A) or anti-ERα (B) antibody. (C and D) Interaction of endogenous
HPIP with endogenous ERα or ERβ in vivo. MCF7 cells, cultured in serum-free
medium for 3 days, were treated without and with 10 nm E2 for 2 h. Cell lysates
were immunoprecipitated with anti-ERβ (C), anti-ERα (D) or preimmune
control serum. The precipitates were analyzed by immunoblot using anti-HPIP.
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and HPIP(221–367)) failed to interact with ERα and ERβ
(Fig. 3). Since full-length GST-HPIP was readily degraded, the
GST-HPIP was not used in the GST pull-down experiments.
3.5. HPIP increases estrogen-responsive reportergene transcription
To determine whether HPIP–ER interaction affects ER
transcriptional activity, ERα- and ERβ-positive MCF7 breast
cancer cells were cotransfected with pS2-Luc, an estrogen-
responsive promoter, and FLAG-HPIP or HPIP small interfer-
ing RNA (siRNA). As shown in Fig. 4A and B, overexpression
of HPIP increased the reporter activity, whereas reduction of
endogenous HPIP with HPIP siRNA decreased the activity.
Taken together, these data indicate that HPIP enhances the pS2
reporter gene transcription.
3.6. HPIP increases ERα target gene expression
To corroborate the results of the luciferase reporter assay, the
effect of HPIP on the expression of endogenous estrogen-
responsive genes were determined. The E2-deprived MCF7
cells stably expressing either the empty vector or HPIP were
treated with E2 and then harvested for immunoblotting. As
expected, E2 stimulated the expression of pS2 and cathepsin D
(Fig. 4C). Importantly, stable transfection of HPIP furtherFig. 3. Mapping of ERα/ERβ interaction region in RBPMS. 35S-labelled in vitro
translated ERα or ERβ was incubated with GST-HPIP(1–137), GST-HPIP
(138–220), GST-HPIP(221–367), GST-HPIP(328–561) or GST-HPIP(562–
731), or with GST. The bound proteins were subjected to SDS-PAGE followed
by autoradiography. SDS-PAGE analysis of the purified GST-fusion proteins is
shown at the bottom.
Fig. 5. HPIP regulates estrogen-responsive protein expression through activation
of MAPK and AKT. (A and B) HPIP activates MAPK and AKT in an ER-
dependent manner. HPIP (A) or HPIP siRNA (B) stably expressed MCF7 cells
were treated with E2 or E2 plus ICI182,780. Cells were harvested for
immunoblotting with antibodies to phospho-MAPK/ERK1/2 (phos-ERK),
ERK1/2, phospho-AKT (phos-AKT) or AKT. (C) Phosphorylation of MAPK
and AKT is responsible for HPIP stimulation of pS2 expression. HPIP stably
expressed MCF7 cells were treated with E2 or E2 plus PD98059 or E2 plus
LY294002. Cell lysates were blotted with the indicated antibodies.
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effects were observed with MCF7 cells stably transfected with
HPIP siRNA (Fig. 4D).Fig. 4. HPIP regulates estrogen-responsive gene expression. (A and B)
Overexpression of HPIP or knockdown of endogenous HPIP modulates pS2
reporter activity. MCF7 cells were cotransfected with 0.2 µg of reporter pS2-Luc
and 1 µg of the expression vector for FLAG-tagged HPIP (A) or HPIP siRNA
(B). Cells were treated with or without 10 nm E2 and analyzed for luciferase
activity. Expression levels of HPIP were shown by immunoblotting with anti-
FLAG (A) or anti-HPIP (B) at the bottom.GAPDHwas used as a loading control.
(C and D) overexpression of HPIP or knockdown of endogenous HPIP
modulates estrogen-responsive protein expression.MCF7 cells stably transfected
with HPIP (C) or HPIP siRNA (D) or corresponding empty vector were cultured
in phenol red-free DMEM and treated with control (0.1% ethanol) vehicle or
10 nM E2 for 24 h. The cells were harvested and lysed, and conditioned medium
was concentrated using a 3-kDa membrane. The concentrate was used for
Western blot analysis of the expression of pS2 and cathepsin D, and the whole
cell lysate was used for Western blot analysis of the expression of HPIP and
GAPDH.
Fig. 6. HPIPmodulates estrogen-responsive gene transcription through increased
ERα phosphorylation. (A) HPIP increases ERα phosphorylation. HPIP or HPIP
siRNA stably expressed MCF7 cells were immunoprecipitated with ERα
antibody and blotted with antibodies to phospho-serine (phos-Ser) and phospho-
ERα (serine 167) or ERα. (B) Mutation of serine 167 in ERα to alanine impairs
HPIP function. MCF7 cells were cotransfected with 0.2 µg of reporter pS2-Luc
and 1 µg of HPIP siRNA construct, together with 50 ng wild-type ERα or mutant
ERα. Cells were treated with or without E2 and analyzed for luciferase activity.
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activation of MAPK and AKT
Since HPIP is predominantly located in the cytoplasm (data
not shown), the potential non-genomic effect of HPIP was
determined using the above HPIP or HPIP siRNA-transfected
stable cell lines. Western blot analysis showed that E2 rapidly
increased phosphorylation of MAPK/ERK1/2 and AKT in
empty vector-transfected MCF7 cells (Fig. 5A). HPIP further
enhanced phosphorylation of MAPK and AKT in HPIP-
transfected cells. This activation of MAPK and AKT could be
abolished by ICI182,780, an ERα antagonist, indicating that
HPIP-mediated activation of MAPK and AKT is ER-dependent
(Fig. 5A). Consistent with the overexpression experiments,
stable knockdown of HPIP with HPIP siRNA in MCF7 cells
reduced MAPK and AKT phosphorylation (Fig. 5B).
To investigate whether activation of MAPK and AKT is
responsible for the enhancement of estrogen-responsive gene
expression by HPIP, PD98059 and LY294002, which are
MAPK and PI3K/AKT inhibitors, respectively, were used to
treat MCF7 cells stably transfected with either HPIP or empty
vector. As expected, the MAPK and AKT inhibitors decreased
phosphorylation of ERK1/2 and AKT, respectively (Fig. 5C).
The pS2 protein expression was impaired, but not abolished, by
the inhibition of ERK1/2 and AKT, in the empty vector and
HPIP stably transfected MCF7 cells at comparable levels. These
data suggest that HPIP regulates pS2 expression at least in part
through activated MAPK and AKT.
3.8. HPIP increases ERα target gene transcription through
enhanced ERα phosphorylation
Although ERβ phosphorylation is largely unknown, ERα
has been shown to be phosphorylated at serine 118 and serine
167 by MAPK and AKT, respectively. Since HPIP can activate
MAPK and AKT, we determined whether HPIP increases
phosphorylation of ERα. As shown in Fig. 6A, overexpression
of HPIP in MCF7 cells by stable transfection with HPIP
increased phosphorylation of ERα at serine residue, whereas
stable knockdown of HPIP with HPIP siRNA decreased ERα
phosphorylation. Furthermore, ectopic expression of HPIP
enhanced phosphorylation of ERα at serine 167, while
reduction of endogenous HPIP with HPIP siRNA reduced
phosphorylation of ERα at serine 167. Importantly, in the pS2
reporter assay, knockdown of HPIP reduced wild-type ERα-
mediated pS2 reporter transcription greater than the pS2
reporter transcription mediated by mutant ERα in which serine
167 was mutated to alanine (Fig. 6B). These data indicate that
phosphorylation of ERα at serine 167 is important for the
enhancement of ERα target gene transcription by HPIP.
3.9. Reduction of ERα binding to HPIP through ERβ competition
and interaction of ERβ with ERα
Since HPIP interacts both with ERα and with ERβ, we
investigated whether ERβ could affect the interaction of ERα
with HPIP. In the presence of increasing levels of ERβ, ERαinteraction with HPIP progressively decreased, whereas ERβ
interaction with HPIP increased, indicating that ERβ can
compete with ERα for binding to HPIP (Fig. 7A).
To test the possibility that ERβ could decrease ERα binding
to HPIP through interaction of ERβ with ERα, coimmunopre-
cipitation experiments were again performed. With the increas-
ing amounts of ERβ, ERα interaction with HPIP progressively
decreased, whereas ERβ interaction with ERα increased,
suggesting that ERβ interacts with ERα and thus decreases
ERα interaction with HPIP (Fig. 7B).
3.10. ERβ negatively regulates ERα target gene expression
Next, we examined whether ERβ could affect ERα target
gene expression. For this purpose, we generated stable
transfectants of MCF7 breast cancer cells with FLAG-tagged
ERβ expression vector. MCF7 cells stably transfected with the
FLAG-tagged ERβ expressed FLAG-ERβ (Fig. 7C). Expres-
sion of the FLAG-ERβ inhibited the expression of the ERα
target gene pS2.
3.11. HPIP regulates breast cancer cell growth
To test the effect of HPIP on breast cancer cell growth, the
growth rate ofMCF7 cells stably transfected with HPIP or empty
Fig. 8. HPIP modulates breast cancer cell growth. FLAG-HPIP (A) or HPIP
siRNA (B) stably expressedMCF7 cells were cultured in regular medium. At the
indicated times, cells were harvested, and the cell number was determined by
crystal violet assay.
Fig. 7. Reduction of ERα binding to HPIP through ERβ competition and
interaction of ERβ with ERα, and negative regulation of ERα target gene
expression by ERβ. (A) Competition between ERβ and ERα for HPIP binding.
The indicated expression constructs were cotransfected into 293T cells. Cell
lysates were immunoprecipitated with anti-FLAG antibody, followed by
immunoblotting with the indicated antibodies. (B) Reduction of ERα binding
to HPIP through interaction of ERβ with ERα. 293T cells were cotransfected
with the indicated plasmids and analyzed as in (A). (C) ERβ inhibition of ERα
target gene expression. MCF7 cells stably transfected with FLAG-ERβ or empty
vector were grown in phenol red-free DMEM and treated with control (0.1%
ethanol) vehicle or 10 nM E2 for 24 h. The cells were harvested and lysed for
Western blot analysis as described in the legend to Fig. 4 C and D.
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MCF7 cells stably transfected with HPIP grew faster than those
with empty vector (at day 5, pb0.05), whereas MCF7 cells
stably transfected with HPIP siRNA grew more slowly than
those with control siRNA (at day 5, pb0.05) (Fig. 8). These
results indicate that HPIP increases breast cancer cell growth.
4. Discussion
In this study, we demonstrated that HPIP physically and
functionally interacts with ER. HPIP increases estrogen-
responsive protein expression in breast cancer cells. Interest-
ingly, HPIP activates MAPK and AKT, which are involved in
the increased expression of estrogen-responsive proteins. To the
best of our knowledge, this is the first evidence for an ER-
interacting protein that not only activates MAPK and AKT but
also potentiates estrogen-responsive gene expression.
While our project was under investigation, Manavathi et al.
reported that HPIP regulates ERα-dependent activation of
MAPK and AKT by recruiting Src kinase and p85 subunit of
PI3K to E2–ERα complex [31]. Consistent with the results
reported by Manavathi et al., we also demonstrated that HPIP
can activate MAPK and AKT. However, we have got a lot of
new results. First, we showed the interaction of ERβ with HPIP
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Manavathi et al. Second, we successfully generated a HPIP-
specific antibody and present evidence of physical interaction
between endogenous HPIP and endogenous ERα/ERβ in
human breast cancer cells using the antibody. HPIP protein is
expressed at varying levels in breast cancer cell lines we
examined. Third, we indicated that HPIP can increase ex-
pression of ERα target genes, including pS2 and cathepsin D,
and activation of MAPK and AKT is responsible for the
increased estrogen-responsive protein expression, suggesting an
important role of HPIP in estrogen signaling. Fourth, we
demonstrated that HPIP increases phosphorylation of ERα at
serine residue, such as serine 167, whose phosphorylation is
involved in ERα transcriptional activity regulated by HPIP.
Fifth, we indicated that ERβ inhibits ERα target gene expres-
sion, possibly by competition of ERβ with ERα for binding to
HPIP, and by a decrease in available ERα for HPIP binding
through interaction of ERβ with ERα. Finally, our study
showed that HPIP can promote breast cancer cell growth in
cultured cells.
Although both our study and that of Manavathi et al. showed
the interaction of HPIP with ERα and HPIP activation of MAPK
and AKT, there are some discrepancies between our study and
that reported byManavathi et al. In our study, both ERα and ERβ
bound three HPIP regions, amino acids 138–220, 328–561, and
562–731, with the first region showing relatively strong
interaction. However, Manavathi et al. reported that amino
acids 1–277 of HPIP, which contains the region 138–220 we
examined, do not interact with ERα. The discrepancy between
our study and that ofManavathi et al. may result from the different
HPIP fragments used in GST pull-down experiments. Although
we showed the interaction of ERα and ERβ with amino acids
138–220 of HPIP, both ERα and ERβ do not interact with the
region 1–138 of HPIP. Combined with the report by Manavathi
et al., these results suggest that the region 1–138 of HPIP may
inhibit the interaction of HPIPwith ER in the context of the region
1–277 of HPIP. Manavathi et al. reported that overexpression of
HPIP in MCF7 inhibits ERα transcriptional activity, as measured
by analysis of the ERE-Luc reporter, a synthetic estrogen-
responsive reporter. Manavathi et al. have not reported the effect
of knockdown of HPIP with HPIP siRNA inMCF7 cells on ERα
transcriptional activity. They also have not shown the effect of
HPIP on the expression of endogenous estrogen-responsive
genes, such as pS2. In our study, overexpression of HPIP in
MCF7 slightly increased ERα transcriptional activity analyzed by
the pS2-Luc reporter, a natural estrogen-responsive reporter,
while knockdown of endogenous HPIP with HPIP siRNA dra-
matically reduced the reporter activity. More importantly, our
study showed that overexpression of HPIP in MCF7 cells
enhanced the pS2 protein expression, whereas reduction of endo-
genous HPIP with HPIP siRNA decreased the pS2 protein
expression, further confirming the results of the reporter assay.
The discrepancy between our study and that of Manavathi et al.
could be due to a different reporter used.
It has been shown that the ligand-independent activity of
ERα is a result of ERα phosphorylation at multiple sites (serine
104, serine 106, serine 118, serine 167, serine 236 and tyr-537)by multiple kinases [19]. For example, serine 118 is a target of
activated MAPK in response to EGF or insulin-like growth
factor (IGF) treatment. However, the identity of the kinase
involved in serine 118 phosphorylation in response to E2 is
controversial. Several kinases, such as AKT and p90 ribosomal
S6 kinase (RSK), have been reported to be responsible for
serine 167 phosphorylation. Our study showed that HPIP
activates MAPK and AKT and increases ERα phosphorylation
at serine residue. Furthermore, we demonstrated that serine 167
phosphorylation is important for HPIP activation of ERα
transcriptional activity because a mutant ERα in which serine
167 is changed to alanine reduced the HPIP function. Although
HPIP can stimulate MAPK and AKT, which are important cell
survival factors, we cannot exclude the possibility that HPIP can
also activate other kinases. It will be interesting to precisely
determine what kinds of kinases are involved in HPIP-mediated
activation of ER signaling.
Like ERα, the more recently discovered ERβ has been
shown to be an important determinant in breast cancer. Contrary
to ERα, ERβ expression generally decreases during breast
tumorigenesis [32–34] Most studies have indicated that ERβ
expression is an indicator of a favorable prognosis for breast
cancer patients [35–38]. Although many ERα-regulated target
genes, such as pS2 and cathepsin D, have been identified and
well characterized, little is known for ERβ-regulated down-
stream genes. We demonstrated for the first time that ERβ can
inhibit ERα target protein expression. Generally speaking, ERα
expression levels are higher than those of ERβ in most breast
cancers, and the majority of breast cancers express ERβ
together with ERα [39–41]. Estrogen via ERα induces pro-
liferation and inhibits apoptosis, whereas ERβ opposes the
proliferative effect of ERα in cultured cells [42]. When ERβ is
cotransfected with ERα, it inhibits ERα-mediated transcrip-
tional activity on an ERE reporter gene, suggesting that ERβ is
a negative regulator of ERα [43]. Our study indicated that ERβ
competes with ERα for binding to HPIP and inhibits the
expression of the ERα-regulated gene pS2. Therefore, the
relative ratio of ERβ to ERα should be an important factor
responsible for HPIP function. Conceivably, cells with lower
ERβ levels and higher HPIP levels might readily develop breast
cancer and have more malignant phenotype. It will be very
interesting to investigate clinical significance of HPIP in breast
cancer.
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